GlassScriptPhysician profile
Marissa Fox
NPI 1356970883
$4,701.26
in general payments reported to CMS, 2019-2025
23 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.93 · 2023: $424 · 2024: $2,517 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,661.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,681.79 | 2023-2025 | Apretude, Cabenuva, Dovato |
| Gilead Sciences, INC. | $1,393.52 | 2024-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $367.65 | 2022-2025 | Pifeltro, Delstrigo, Capvaxive |
| Abbvie INC. | $258.69 | 2023-2025 | |
| Napo Pharmaceuticals INC | $145.43 | 2024-2025 | Mytesi |
| Emd Serono, INC. | $123.45 | 2023-2024 | Serostim |
| Lilly USA, LLC | $117.58 | 2024-2025 | Zepbound, Mounjaro |
| Bausch Health US, LLC | $102.88 | 2024-2025 | Aplenzin |
| Antares Pharma, INC. | $63.52 | 2024 | Xyosted |
| Glaxosmithkline, LLC. | $62.65 | 2023-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.89 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.68 | 2024 | Caplyta |
| Amgen INC. | $48.04 | 2024 | Repatha, Otezla |
| Theratechnologies INC. | $37.27 | 2024 | Trogarzo, Egrifta |
| Exact Sciences Corporation | $36.37 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $24.24 | 2024 | Qelbree |
| Axsome Therapeutics, INC. | $23.47 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.60 | 2023 | Quviviq |
| Novo Nordisk INC | $18.60 | 2025 | Wegovy |
| Pfizer INC. | $17.84 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $17.20 | 2024 | Airsupra |
| Corium, LLC | $17.00 | 2024 | Azstarys |
| Almatica Pharma LLC | $16.90 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.